von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4
Levels of von Willebrand factor antigen (vWF-Ag) increase during combination antiviral therapy of chronic hepatitis C (CHC). The present study investigates the association between these changes in vWF-Ag levels and response to treatment. Changes in levels of vWF-Ag on antiviral combination treatment...
Gespeichert in:
| Veröffentlicht in: | Antiviral therapy 2010-01, Vol.15 (6), p.831-839 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 839 |
|---|---|
| container_issue | 6 |
| container_start_page | 831 |
| container_title | Antiviral therapy |
| container_volume | 15 |
| creator | PRAMHAS, Sibylle HOMONCIK, Monika FERENCI, Peter FERLITSCH, Arnulf SCHERZER, Thomas GANGL, Alfred PECK-RADOSAVLJEVIC, Markus |
| description | Levels of von Willebrand factor antigen (vWF-Ag) increase during combination antiviral therapy of chronic hepatitis C (CHC). The present study investigates the association between these changes in vWF-Ag levels and response to treatment.
Changes in levels of vWF-Ag on antiviral combination treatment in 184 patients with CHC genotype 1 or 4 infections were measured prospectively and effect on response was studied.
High on-treatment levels of vWF-Ag were associated with relapse (P |
| doi_str_mv | 10.3851/IMP1654 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_858421965</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>858421965</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-eff659db86d915dd64f6fc6601dfccd48251f65d2a0d15579c97ff57491d235f3</originalsourceid><addsrcrecordid>eNqF0U1vEzEQBmALgWgoiH-A5oI4Lfhz1-aGIj4qFbWHIo4rxx4To4292E6k_AL-drcl0COnuTzzjjQvIS8ZfSu0Yu8uvl6zXslHZMWppB2nSj8mKyaU6Xol1Bl5VutPSrk2lD4lZ5xqIalRK_L7kBN8j9OEm2KTh2BdywVsavEHpvdgIeUDTpBT1wratsPUYC7o473LAQrWOaeK0PL92iEWO0HbYrHzEWICty05RQdbnG2LLVZYw5Kd23HGCgzuzsrn5EmwU8UXp3lOvn36eLP-0l1efb5Yf7jsnBhU6zCEXhm_0b03THnfy9AH1_eU-eCcl5ortgjPLfVMqcE4M4SgBmmY50IFcU7e_MmdS_61x9rGXawOp8kmzPs6aqUlZ2Z52v_koCSlzAzmQbqSay0YxrnEnS3HkdHxrp7xVM8iX50y95sd-n_ubx8LeH0Ctjo7haUTF-uDE1zTgQlxC64FmEo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>754001979</pqid></control><display><type>article</type><title>von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4</title><source>MEDLINE</source><source>Sage Journals GOLD Open Access 2024</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>PRAMHAS, Sibylle ; HOMONCIK, Monika ; FERENCI, Peter ; FERLITSCH, Arnulf ; SCHERZER, Thomas ; GANGL, Alfred ; PECK-RADOSAVLJEVIC, Markus</creator><creatorcontrib>PRAMHAS, Sibylle ; HOMONCIK, Monika ; FERENCI, Peter ; FERLITSCH, Arnulf ; SCHERZER, Thomas ; GANGL, Alfred ; PECK-RADOSAVLJEVIC, Markus</creatorcontrib><description>Levels of von Willebrand factor antigen (vWF-Ag) increase during combination antiviral therapy of chronic hepatitis C (CHC). The present study investigates the association between these changes in vWF-Ag levels and response to treatment.
Changes in levels of vWF-Ag on antiviral combination treatment in 184 patients with CHC genotype 1 or 4 infections were measured prospectively and effect on response was studied.
High on-treatment levels of vWF-Ag were associated with relapse (P<0.01) and low on-treatment levels with sustained virological response (SVR). Receiver operating characteristic curve analysis showed that vWF-Ag levels of <300% at week 12 of therapy have a positive predictive value (PPV) of 78% for SVR. In early virological response (EVR) patients, the PPV of vWF-Ag levels <300% at week 12 was 74%. An even higher PPV of 88% in complete EVRs (undetectable HCV RNA at week 12) was observed for the same cutoff value at week 12.
On-treatment levels of vWF-Ag can be utilized as an additional predictive marker for response to antiviral therapy. This is especially relevant in EVR patients because EVR alone only has a PPV of 58-72% on SVR, which increased to 74%, when factoring in vWF-Ag levels <300% at week 12, and to 88% in complete EVRs; therefore, measurement of vWF-Ag levels at week 12 is helpful. EVR patients that are above the cutoff values for vWF-Ag that make SVR very probable might profit from an extension of therapy to 72 weeks.</description><identifier>ISSN: 1359-6535</identifier><identifier>EISSN: 2040-2058</identifier><identifier>DOI: 10.3851/IMP1654</identifier><identifier>PMID: 20834095</identifier><language>eng</language><publisher>London: International Medical Press</publisher><subject>Administration, Oral ; Adult ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; Drug Therapy, Combination ; Female ; Genotype ; Hepatitis C virus ; Hepatitis C, Chronic - drug therapy ; Human viral diseases ; Humans ; Infectious diseases ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Predictive Value of Tests ; Prospective Studies ; Recurrence ; Ribavirin - administration & dosage ; Ribavirin - therapeutic use ; Viral diseases ; Viral hepatitis ; von Willebrand Factor - immunology ; von Willebrand Factor - metabolism</subject><ispartof>Antiviral therapy, 2010-01, Vol.15 (6), p.831-839</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-eff659db86d915dd64f6fc6601dfccd48251f65d2a0d15579c97ff57491d235f3</citedby><cites>FETCH-LOGICAL-c375t-eff659db86d915dd64f6fc6601dfccd48251f65d2a0d15579c97ff57491d235f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23280713$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20834095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PRAMHAS, Sibylle</creatorcontrib><creatorcontrib>HOMONCIK, Monika</creatorcontrib><creatorcontrib>FERENCI, Peter</creatorcontrib><creatorcontrib>FERLITSCH, Arnulf</creatorcontrib><creatorcontrib>SCHERZER, Thomas</creatorcontrib><creatorcontrib>GANGL, Alfred</creatorcontrib><creatorcontrib>PECK-RADOSAVLJEVIC, Markus</creatorcontrib><title>von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4</title><title>Antiviral therapy</title><addtitle>Antivir Ther</addtitle><description>Levels of von Willebrand factor antigen (vWF-Ag) increase during combination antiviral therapy of chronic hepatitis C (CHC). The present study investigates the association between these changes in vWF-Ag levels and response to treatment.
Changes in levels of vWF-Ag on antiviral combination treatment in 184 patients with CHC genotype 1 or 4 infections were measured prospectively and effect on response was studied.
High on-treatment levels of vWF-Ag were associated with relapse (P<0.01) and low on-treatment levels with sustained virological response (SVR). Receiver operating characteristic curve analysis showed that vWF-Ag levels of <300% at week 12 of therapy have a positive predictive value (PPV) of 78% for SVR. In early virological response (EVR) patients, the PPV of vWF-Ag levels <300% at week 12 was 74%. An even higher PPV of 88% in complete EVRs (undetectable HCV RNA at week 12) was observed for the same cutoff value at week 12.
On-treatment levels of vWF-Ag can be utilized as an additional predictive marker for response to antiviral therapy. This is especially relevant in EVR patients because EVR alone only has a PPV of 58-72% on SVR, which increased to 74%, when factoring in vWF-Ag levels <300% at week 12, and to 88% in complete EVRs; therefore, measurement of vWF-Ag levels at week 12 is helpful. EVR patients that are above the cutoff values for vWF-Ag that make SVR very probable might profit from an extension of therapy to 72 weeks.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Genotype</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Predictive Value of Tests</subject><subject>Prospective Studies</subject><subject>Recurrence</subject><subject>Ribavirin - administration & dosage</subject><subject>Ribavirin - therapeutic use</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>von Willebrand Factor - immunology</subject><subject>von Willebrand Factor - metabolism</subject><issn>1359-6535</issn><issn>2040-2058</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0U1vEzEQBmALgWgoiH-A5oI4Lfhz1-aGIj4qFbWHIo4rxx4To4292E6k_AL-drcl0COnuTzzjjQvIS8ZfSu0Yu8uvl6zXslHZMWppB2nSj8mKyaU6Xol1Bl5VutPSrk2lD4lZ5xqIalRK_L7kBN8j9OEm2KTh2BdywVsavEHpvdgIeUDTpBT1wratsPUYC7o473LAQrWOaeK0PL92iEWO0HbYrHzEWICty05RQdbnG2LLVZYw5Kd23HGCgzuzsrn5EmwU8UXp3lOvn36eLP-0l1efb5Yf7jsnBhU6zCEXhm_0b03THnfy9AH1_eU-eCcl5ortgjPLfVMqcE4M4SgBmmY50IFcU7e_MmdS_61x9rGXawOp8kmzPs6aqUlZ2Z52v_koCSlzAzmQbqSay0YxrnEnS3HkdHxrp7xVM8iX50y95sd-n_ubx8LeH0Ctjo7haUTF-uDE1zTgQlxC64FmEo</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>PRAMHAS, Sibylle</creator><creator>HOMONCIK, Monika</creator><creator>FERENCI, Peter</creator><creator>FERLITSCH, Arnulf</creator><creator>SCHERZER, Thomas</creator><creator>GANGL, Alfred</creator><creator>PECK-RADOSAVLJEVIC, Markus</creator><general>International Medical Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20100101</creationdate><title>von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4</title><author>PRAMHAS, Sibylle ; HOMONCIK, Monika ; FERENCI, Peter ; FERLITSCH, Arnulf ; SCHERZER, Thomas ; GANGL, Alfred ; PECK-RADOSAVLJEVIC, Markus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-eff659db86d915dd64f6fc6601dfccd48251f65d2a0d15579c97ff57491d235f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Genotype</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Predictive Value of Tests</topic><topic>Prospective Studies</topic><topic>Recurrence</topic><topic>Ribavirin - administration & dosage</topic><topic>Ribavirin - therapeutic use</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>von Willebrand Factor - immunology</topic><topic>von Willebrand Factor - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PRAMHAS, Sibylle</creatorcontrib><creatorcontrib>HOMONCIK, Monika</creatorcontrib><creatorcontrib>FERENCI, Peter</creatorcontrib><creatorcontrib>FERLITSCH, Arnulf</creatorcontrib><creatorcontrib>SCHERZER, Thomas</creatorcontrib><creatorcontrib>GANGL, Alfred</creatorcontrib><creatorcontrib>PECK-RADOSAVLJEVIC, Markus</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Antiviral therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PRAMHAS, Sibylle</au><au>HOMONCIK, Monika</au><au>FERENCI, Peter</au><au>FERLITSCH, Arnulf</au><au>SCHERZER, Thomas</au><au>GANGL, Alfred</au><au>PECK-RADOSAVLJEVIC, Markus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4</atitle><jtitle>Antiviral therapy</jtitle><addtitle>Antivir Ther</addtitle><date>2010-01-01</date><risdate>2010</risdate><volume>15</volume><issue>6</issue><spage>831</spage><epage>839</epage><pages>831-839</pages><issn>1359-6535</issn><eissn>2040-2058</eissn><abstract>Levels of von Willebrand factor antigen (vWF-Ag) increase during combination antiviral therapy of chronic hepatitis C (CHC). The present study investigates the association between these changes in vWF-Ag levels and response to treatment.
Changes in levels of vWF-Ag on antiviral combination treatment in 184 patients with CHC genotype 1 or 4 infections were measured prospectively and effect on response was studied.
High on-treatment levels of vWF-Ag were associated with relapse (P<0.01) and low on-treatment levels with sustained virological response (SVR). Receiver operating characteristic curve analysis showed that vWF-Ag levels of <300% at week 12 of therapy have a positive predictive value (PPV) of 78% for SVR. In early virological response (EVR) patients, the PPV of vWF-Ag levels <300% at week 12 was 74%. An even higher PPV of 88% in complete EVRs (undetectable HCV RNA at week 12) was observed for the same cutoff value at week 12.
On-treatment levels of vWF-Ag can be utilized as an additional predictive marker for response to antiviral therapy. This is especially relevant in EVR patients because EVR alone only has a PPV of 58-72% on SVR, which increased to 74%, when factoring in vWF-Ag levels <300% at week 12, and to 88% in complete EVRs; therefore, measurement of vWF-Ag levels at week 12 is helpful. EVR patients that are above the cutoff values for vWF-Ag that make SVR very probable might profit from an extension of therapy to 72 weeks.</abstract><cop>London</cop><pub>International Medical Press</pub><pmid>20834095</pmid><doi>10.3851/IMP1654</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6535 |
| ispartof | Antiviral therapy, 2010-01, Vol.15 (6), p.831-839 |
| issn | 1359-6535 2040-2058 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_858421965 |
| source | MEDLINE; Sage Journals GOLD Open Access 2024; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Administration, Oral Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - therapeutic use Biological and medical sciences Drug Therapy, Combination Female Genotype Hepatitis C virus Hepatitis C, Chronic - drug therapy Human viral diseases Humans Infectious diseases Male Medical sciences Middle Aged Pharmacology. Drug treatments Predictive Value of Tests Prospective Studies Recurrence Ribavirin - administration & dosage Ribavirin - therapeutic use Viral diseases Viral hepatitis von Willebrand Factor - immunology von Willebrand Factor - metabolism |
| title | von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T12%3A15%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=von%20Willebrand%20factor%20antigen:%20a%20novel%20on-treatment%20predictor%20of%20response%20to%20antiviral%20therapy%20in%20chronic%20hepatitis%20C%20genotypes%201%20and%204&rft.jtitle=Antiviral%20therapy&rft.au=PRAMHAS,%20Sibylle&rft.date=2010-01-01&rft.volume=15&rft.issue=6&rft.spage=831&rft.epage=839&rft.pages=831-839&rft.issn=1359-6535&rft.eissn=2040-2058&rft_id=info:doi/10.3851/IMP1654&rft_dat=%3Cproquest_cross%3E858421965%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=754001979&rft_id=info:pmid/20834095&rfr_iscdi=true |